{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-060033","form_type":"8-K","ticker":null,"cik":"0001651311","company_name":"Merus N.V.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.982631+00:00","generated_at":"2026-06-05T02:42:36.329195+00:00","sec_items":["1.01","3.02"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Merus enters $56M upfront collaboration with Gilead for trispecific antibody programs; potential $1.5B milestones","bullets":["Gilead pays $56M upfront for rights to Merus' Triclonics platform; up to two more programs at $28M each.","Total potential milestones up to ~$1.5B across three programs; tiered royalties mid-single to low double digits.","Gilead purchases 452,527 shares at $55.2454/share (~$25M) in private placement; no transfer for set period.","Merus may elect 50/50 profit-loss share for third program after first IND filing instead of milestones/royalties.","Agreement covers at least two preclinical programs; Gilead has exclusive option per program to license and commercialize."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-060033","json":"https://secwatch.observer/filing/0001193125-24-060033.json","markdown":"https://secwatch.observer/filing/0001193125-24-060033.md","text":"https://secwatch.observer/filing/0001193125-24-060033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/d815831d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:42:36.329195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25ecc30161213b6ba8f786718aa4a2d886101133","claim":"Merus N.V. entered into Collaboration Agreement with Gilead Sciences, Inc. valued at $56 million (effective 2024-03-05).","evidence_excerpt":"On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Value","value":"$56 million"},{"label":"Effective","value":"2024-03-05"}],"fact_type":"material_agreement"},{"claim_id":"fd7b52887045368b032d6e47a8d2cf56e6a091fa","claim":"Merus N.V. entered into Share Subscription Agreement with Gilead Sciences, Inc. (effective 2024-03-05).","evidence_excerpt":"On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Effective","value":"2024-03-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}